8月7日，
DARA BioSciences公司已与 Seyer Pharmatec 公司签订一份在波多黎各销售Soltamox（柠檬酸三苯氧胺、口服剂溶液）的独家分销协议。

Published 17 August 2012

DARA BioSciences has signed an exclusive distribution agreement with Seyer Pharmatec for Soltamox (tamoxifen citrate, oral solution) in the Commonwealth of Puerto Rico.

The company considers launching Soltamox, the FDA-approved oral liquid formulation of tamoxifen citrate, a first-line therapy for the prevention and treatment of breast cancer, later in 2012.

DARA chief executive officer David Drutz said the exclusive agreement with Seyer Pharmatec to sell and distribute Soltamox in Puerto Rico leverages DARA's existing commercial infrastructure, provides DARA with a well-respected and established commercial partner, and presents an opportunity to make Soltamox and potential future cancer-support products readily available for patients.

"Since DARA has exclusive rights to market Soltamox in the United States and its territories and possessions, our partnership with Seyer Pharmatec will help us maximize Soltamox sales," Drutz added.

The company believes that the availability of liquid tamoxifen offers women with breast cancer a convenient and easy-to-swallow alternative.